---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-336681"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2026-08-06T11:04:02+00:00"
generated_at: "2026-08-06T11:06:24.318881+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa Q2 2026 net loss $43.4M; cash $626M; MRT-8102 GFORCE-1 readout H2 2026

## Summary
- Net loss of $43.4M in Q2 2026 vs $12.3M in Q2 2025; collaboration revenue $9.0M vs $23.2M.
- Cash, equivalents, and marketable securities $626.0M as of June 30, 2026; expected to fund operations into 2029.
- MRT-8102 GFORCE-1 study fully enrolled; readout of CRP and calprotectin data expected H2 2026.
- Novartis activated Phase 2 study of MRT-6160 (DDY391) in Sjögren's disease; Monte Rosa eligible for milestone.
- MODeFIRe-1 Phase 2 study of MRT-2359 in mCRPC with AR mutations activated; first patient dosing expected Q3 2026.

## SEC filing metadata
- accession: 0001193125-26-336681
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2026-08-06T11:04:02+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000119312526336681/0001193125-26-336681-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000119312526336681/glue-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-336681
- JSON: https://secwatch.observer/filing/0001193125-26-336681.json
- Plain text: https://secwatch.observer/filing/0001193125-26-336681.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.